Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HP-3020 transdermal palonosetron pharmacokinetic crossover study in healthy men
NL-OMON34113Active, not recruiting
- Sponsor
- Hisamitsu Pharmaceutical Co., Inc.
- Start
- Sep 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of palonosetron in Nausea and Vomiting (2 cohorts), sponsored by Hisamitsu Pharmaceutical Co., Inc. Primary endpoints: Pharmacokinetics of palonosetron in plasma after three 24-hour HP-3020 patch sizes versus intravenous palonosetron, Pharmacokinetics of palonosetron in plasma after 54 cm2 HP-3020 patch for 168 hours and 2 more. Started Sep 2010; status: active, not recruiting.
02
Drugs
palonosetron
03
Conditions
Nausea and Vomiting
Beyond the preview
Go deeper on NL-OMON34113.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON34113.